Literature DB >> 12825943

Nuclear hormone receptor targeted virtual screening.

Matthieu Schapira1, Ruben Abagyan, Maxim Totrov.   

Abstract

Virtual library screening (VLS) is emerging as a valuable drug lead discovery tool. ICM-VLS implementation of this technology was evaluated on a benchmark set of nuclear hormone receptors (NRs), an important therapeutic target family. Over 5000 structurally diverse compounds, including 78 known NR ligands, were screened against 18 crystal structures and one computer model of 10 NR ligand binding domains in their active or inactive states. The results confirm the ability of the VLS method to generate highly focused subsets of the input chemical library, enriched 33- to 100-fold for all but one receptor studied. However, receptor flexibility remains to be fully addressed, and the choice of the specific conformation used for screening may determine the success of the exercise. We observe that for a particular ligand VLS can often identify the correct target within the receptor family, although the technology is unable to reliably discriminate between the closely related receptor isoforms. Additionally, our results suggest that VLS may be applied successfully without an experimental structure of the receptor by using a homology model. These data represent a realistic snapshot of the state-of-the-art of NR-targeted VLS and define the recent progress and the remaining limitations of the technology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825943     DOI: 10.1021/jm0300173

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  46 in total

1.  Molecular mechanism of serotonin transporter inhibition elucidated by a new flexible docking protocol.

Authors:  Mari Gabrielsen; Rafał Kurczab; Aina W Ravna; Irina Kufareva; Ruben Abagyan; Zdzisław Chilmonczyk; Andrzej J Bojarski; Ingebrigt Sylte
Journal:  Eur J Med Chem       Date:  2011-10-20       Impact factor: 6.514

2.  ZINC--a free database of commercially available compounds for virtual screening.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

3.  Surrogate docking: structure-based virtual screening at high throughput speed.

Authors:  Sukjoon Yoon; Andrew Smellie; David Hartsough; Anton Filikov
Journal:  J Comput Aided Mol Des       Date:  2005-11-16       Impact factor: 3.686

4.  Benchmarking sets for molecular docking.

Authors:  Niu Huang; Brian K Shoichet; John J Irwin
Journal:  J Med Chem       Date:  2006-11-16       Impact factor: 7.446

5.  Design of ligand binding to an engineered protein cavity using virtual screening and thermal up-shift evaluation.

Authors:  Claudia Machicado; Jon López-Llano; Santiago Cuesta-López; Marta Bueno; Javier Sancho
Journal:  J Comput Aided Mol Des       Date:  2005-06       Impact factor: 3.686

Review 6.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling.

Authors:  S Ekins; J Mestres; B Testa
Journal:  Br J Pharmacol       Date:  2007-06-04       Impact factor: 8.739

Review 7.  Flexible ligand docking to multiple receptor conformations: a practical alternative.

Authors:  Maxim Totrov; Ruben Abagyan
Journal:  Curr Opin Struct Biol       Date:  2008-02-25       Impact factor: 6.809

8.  An inverse docking approach for identifying new potential anti-cancer targets.

Authors:  Sam Z Grinter; Yayun Liang; Sheng-You Huang; Salman M Hyder; Xiaoqin Zou
Journal:  J Mol Graph Model       Date:  2011-01-19       Impact factor: 2.518

9.  Modulation of Transcription mediated by the Vitamin D Receptor and the Peroxisome Proliferator-Activated Receptor δ in the presence of GW0742 analogs.

Authors:  Kelly Teske; Premchendar Nandhikonda; Jonathan W Bogart; Belaynesh Feleke; Preetpal Sidhu; Nina Yuan; Joshua Preston; Robin Goy; Leggy A Arnold
Journal:  J Biomol Res Ther       Date:  2014

10.  Virtual Screening as a Technique for PPAR Modulator Discovery.

Authors:  Stephanie N Lewis; Josep Bassaganya-Riera; David R Bevan
Journal:  PPAR Res       Date:  2009-09-02       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.